GlassScriptPhysician profile
Eladio S Carrera
NPI 1508967605
$13,114.38
in general payments reported to CMS, 2019-2025
34 companies · $2,820 in 2025
The $2,820 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,025 · 2020: $1,340 · 2021: $1,123 · 2022: $2,087 · 2023: $2,266 · 2024: $2,453 · 2025: $2,820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,539.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,652.04 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Qol Medical, LLC | $1,169.12 | 2019-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $1,106.31 | 2019-2025 | Tremfya, Stelara, Simponi |
| Genzyme Corporation | $794.33 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $720.27 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $576.96 | 2019-2025 | Entyvio, Eohilia |
| Ardelyx, INC. | $522.95 | 2023-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $417.97 | 2023 | Dupixent |
| Braintree Laboratories, INC. | $345.60 | 2020-2022 | |
| Aimmune Therapeutics, INC. | $345.53 | 2024-2025 | Zenpep, Vowst |
| Nestle Healthcare Nutrition INC. | $323.09 | 2021-2023 | |
| Pfizer INC. | $297.07 | 2019-2025 | |
| Redhill Biopharma INC. | $287.47 | 2021-2023 | Talicia |
| Madrigal Pharmaceuticals | $287.14 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $268.41 | 2019-2024 | Dificid, Zinplava |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $266.64 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $263.46 | 2021-2023 | Linzess |
| Celltrion USA INC. | $212.98 | 2025 | Zymfentra, Vegzelma |
| Enterra Medical, INC. | $165.92 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $155.32 | 2022-2024 | Farxiga |
| Lilly USA, LLC | $149.10 | 2023-2024 | Omvoh |
| Phathom Pharmaceuticals, INC. | $143.74 | 2024-2025 | Voquezna |
| Janssen Scientific Affairs, LLC | $131.32 | 2022 | |
| Esperion Therapeutics, INC. | $130.00 | 2024 | Nexlizet, Nexletol |
| Organon LLC | $63.96 | 2023-2024 | Hadlima, Renflexis |
| Ferring Pharmaceuticals INC. | $50.05 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $47.94 | 2023-2024 | Ocaliva |
| Orphalan INC | $45.53 | 2024-2025 | Cuvrior |
| Ethicon US, LLC | $41.45 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $40.31 | 2025 | Iqirvo |
| Intra-Sana Laboratories | $29.90 | 2021-2022 | |
| Glaxosmithkline, LLC. | $25.54 | 2020 | |
| Boston Scientific Corporation | $22.66 | 2023 | Exalt Model D |
| Novo Nordisk INC | $14.30 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eladio Carrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.